{"schema_version":"1.0","type":"article","title":"Taiwan ADC companies: OBI leads, biosimilar first","url":"https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110-en.md","lang":"en","date":"2026-10-30","publish_at":"2026-10-30T08:00:00+08:00","updated_at":"2026-10-30","category":"商業分析系列","topic":"公司研究","tags":["Taiwan ADC companies","antibody-drug conjugate","OBI Pharma OBI-992","Formosa Pharmaceuticals TSY-110","GlycoNex GNX1021"],"summary":"BioNTech just called its HER2 ADC's benefit limited while Roche paid $400M upfront for Hansoh's ADC platform. Where do Taiwan's 7 ADC companies stand? OBI leads on novel drugs; a Kadcyla biosimilar gets to market first.","key_points":["TSY-110, the Kadcyla biosimilar from Formosa Pharmaceuticals (6838) and EirGenix (6589), will be Taiwan's first ADC in pivotal development: Formosa filed a European clinical trial application on August 28, 2026, and this analysis expects first-patient dosing to be announced by June 30, 2027.","OBI Pharma (4174) has the most advanced Taiwan-owned novel ADC, the TROP2 drug OBI-992: its Phase 1/2 trial began June 12, 2024, at eight US and Taiwan sites with about 117 planned patients, has set a recommended Phase 2 dose, and showed partial responses in three patients by December 2025.","Taiwan's ADC sector runs on three paths: novel drugs (OBI; GlycoNex, whose GNX1021 enrolled its first patient in Japan in August 2026; Chia-Cheng's ARC), a biosimilar (TSY-110) and contract manufacturing (Formosa Laboratories, Mycenax, EirGenix), while global buyers pay for platforms, as Roche's $400 million upfront to Hansoh on October 19, 2026, shows."],"facts":[{"claim":"BioNTech–DualityBio 2023 ADC license, potential total value (up to)","value":1.6,"unit":"US$ billion","as_of":"2026-10-26","source":"https://www.biopharmadive.com/news/biontech-dualitybio-modest-results-adc-breast-cancer/839574/"},{"claim":"Roche upfront payment to Hansoh in the October 2026 ADC deal","value":0.4,"unit":"US$ billion","as_of":"2026-10-19","source":"https://www.pharmexec.com/view/hansoh-pharma-15-billion-collaboration-license-agreement-roche"},{"claim":"Roche first-anniversary payment to Hansoh","value":0.11,"unit":"US$ billion","as_of":"2026-10-19","source":"https://www.pharmexec.com/view/hansoh-pharma-15-billion-collaboration-license-agreement-roche"},{"claim":"Roche–Hansoh ADC deal potential milestones (more than)","value":15,"unit":"US$ billion","as_of":"2026-10-19","source":"https://www.pharmexec.com/view/hansoh-pharma-15-billion-collaboration-license-agreement-roche"},{"claim":"OBI-992 Phase 1/2 trial (NCT06480240) estimated enrollment","value":117,"unit":"patients","as_of":"2024-06-12","source":"https://clinicaltrials.gov/study/NCT06480240"},{"claim":"OBI-992 trial sites (6 US, 2 Taiwan)","value":8,"unit":"sites","as_of":"2024-06-12","source":"https://clinicaltrials.gov/study/NCT06480240"},{"claim":"OBI-992 Phase 1/2 trial start date","value":"2024-06-12","unit":"date","as_of":"2024-06-12","source":"https://clinicaltrials.gov/study/NCT06480240"},{"claim":"Drug-to-antibody ratio range supported by OBI's GlycOBI platform","value":"2–16","unit":"warheads per antibody","as_of":"2026-10-27","source":"https://www.obipharma.com/what-we-do/pipeline-overview/"},{"claim":"OBI-992 patients with partial tumor responses reported at OBI's investor conference","value":3,"unit":"patients","as_of":"2025-12-18","source":"https://www.ctee.com.tw/news/20251218701436-430504"},{"claim":"OBI Pharma Q3 2025 standalone revenue growth vs Q2, driven by ADC technology collaborations","value":289,"unit":"%","as_of":"2025-12-18","source":"https://www.ctee.com.tw/news/20251218701436-430504"},{"claim":"Board approval date of OBI's global glycoprotein ADC license to TegMine","value":"2025-12-19","unit":"date","as_of":"2025-12-19","source":"https://wantrich.chinatimes.com/news/20251219900409-420101"},{"claim":"GlycoNex announcement date of first patient enrolled in Japan for GNX1021","value":"2026-08-03","unit":"date","as_of":"2026-08-03","source":"https://www.ctee.com.tw/news/20260803700603-430504"},{"claim":"Chia-Cheng Biotech ADC technology license fee from Taiwan's biotech center (2023)","value":690,"unit":"NT$ million","as_of":"2023-03-13","source":"https://www.mirrormedia.mg/story/20230313ind006"},{"claim":"Chia-Cheng and Ji-Sheng ARC memorandum signing date","value":"2026-01-19","unit":"date","as_of":"2026-01-19","source":"https://technews.tw/2026/01/19/arc/"},{"claim":"Formosa Pharmaceuticals TSY-110 EU clinical trial application announcement date","value":"2026-08-28","unit":"date","as_of":"2026-08-28","source":"https://www.biopharminternational.com/view/formosa-pharmaceuticals-eu-trastuzumab-emtansine-biosimilar-tsy-110"},{"claim":"Roche Kadcyla 2025 global sales (about)","value":2.5,"unit":"US$ billion","as_of":"2026-09-03","source":"https://www.biopharminternational.com/view/formosa-pharmaceuticals-eu-trastuzumab-emtansine-biosimilar-tsy-110"},{"claim":"EirGenix trastuzumab biosimilar EG12014 approval in Taiwan","value":"2023-06","unit":"year-month","as_of":"2026-09-03","source":"https://www.biopharminternational.com/view/formosa-pharmaceuticals-eu-trastuzumab-emtansine-biosimilar-tsy-110"},{"claim":"GlobalData forecast for Kadcyla plus Enhertu global market in 2031","value":13.3,"unit":"US$ billion","as_of":"2026-10-27","source":"https://www.formosapharma.com/tsy-0110/"},{"claim":"EirGenix total manufacturing capacity","value":29.6,"unit":"kL","as_of":"2026-10-21","source":"https://geneonline.news/cphi-milan-2026-eirgenix-event-034-oct-2026/"},{"claim":"Drug-to-antibody ratio supported by Mycenax's in-house MMA linker","value":"4–8","unit":"warheads per antibody","as_of":"2026-08-21","source":"https://geneonline.news/mycenax-emerging-biologics-summit-asia-adc-034/"}],"sections":["01｜ADC buyers only pay for what others cannot build","02｜One ruler: how far each Taiwan ADC company has come","03｜OBI Pharma is furthest ahead, and its platform already earns","04｜GlycoNex and Chia-Cheng bet on targets no one else is mining","05｜Taiwan's first ADC on the market will be a biosimilar","Taiwan stock angle","References"],"references":[{"title":"BioNTech, DualityBio say ADC had 'modest' benefit in breast cancer study","source":"BioPharma Dive","date":"2026-10-26","url":"https://www.biopharmadive.com/news/biontech-dualitybio-modest-results-adc-breast-cancer/839574/"},{"title":"Hansoh Pharma enters $15 billion collaboration and license agreement with Roche","source":"Pharmaceutical Executive","date":"2026-10-19","url":"https://www.pharmexec.com/view/hansoh-pharma-15-billion-collaboration-license-agreement-roche"},{"title":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors (NCT06480240","source":"ClinicalTrials.gov","date":"2024-06-12","url":"https://clinicaltrials.gov/study/NCT06480240"},{"title":"Pipeline overview","source":"OBI Pharma","date":"2026-10-27","url":"https://www.obipharma.com/what-we-do/pipeline-overview/"},{"title":"OBI Pharma investor conference: ADC platform commercialization, three partial responses for OBI-992","source":"Commercial Times","date":"2025-12-18","url":"https://www.ctee.com.tw/news/20251218701436-430504"},{"title":"OBI Pharma signs glycoprotein ADC license with TegMine Therapeutics","source":"Wantrich (China Times","date":"2025-12-19","url":"https://wantrich.chinatimes.com/news/20251219900409-420101"},{"title":"Merck's sac-TMT posts major PFS benefit in PD-L1-negative NSCLC","source":"Fierce Pharma","date":"2026-10-25","url":"https://www.fiercepharma.com/pharma/merck-kelun-workhorse-adc-posts-major-tumor-progression-benefit-pd-l1-negative-nsclc"},{"title":"GlycoNex GNX1021 enrolls first patient in Japan","source":"Commercial Times","date":"2026-08-03","url":"https://www.ctee.com.tw/news/20260803700603-430504"},{"title":"Ji-Sheng and Chia-Cheng form alliance on antibody-radiation conjugates","source":"TechNews","date":"2026-01-19","url":"https://technews.tw/2026/01/19/arc/"},{"title":"Chia-Cheng licenses ADC technology from Taiwan's biotech center for NT$690 million","source":"Mirror Media","date":"2023-03-13","url":"https://www.mirrormedia.mg/story/20230313ind006"},{"title":"Formosa Pharmaceuticals files EU application for trastuzumab emtansine biosimilar TSY-110","source":"BioPharm International","date":"2026-09-03","url":"https://www.biopharminternational.com/view/formosa-pharmaceuticals-eu-trastuzumab-emtansine-biosimilar-tsy-110"},{"title":"Kadcyla Biosimilar","source":"TSY-0110","date":"2026-10-27","url":"https://www.formosapharma.com/tsy-0110/"},{"title":"CPHI Milan 2026: EirGenix shows dual-engine CDMO capacity and global reach","source":"GeneOnline","date":"2026-10-21","url":"https://geneonline.news/cphi-milan-2026-eirgenix-event-034-oct-2026/"},{"title":"Mycenax builds a cross-border ADC CDMO ecosystem","source":"GeneOnline","date":"2026-08-21","url":"https://geneonline.news/mycenax-emerging-biologics-summit-asia-adc-034/"}],"images":[{"alt":"Fig. 1｜How an ADC kills a cancer cell, and which part each Taiwanese company changes","url":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110-en/figure-01.png"},{"alt":"Fig. 2｜Where Taiwan's seven ADC companies stand","url":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110-en/figure-02.png"},{"alt":"Fig. 3｜Taiwan's ADC timeline","url":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110-en/figure-03.png"},{"alt":"Fig. 4｜How big ADC money is","url":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-30）。Taiwan ADC companies: OBI leads, biosimilar first。https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}